ELAN stock sentiment todayElanco Animal Health Incorporated
Sentiment verdict
Gossip first, financials second — HOT at 78% confidence.
Last updated · cached analysis, refreshes periodically
ELAN
Elanco Animal Health IncorporatedElanco is hitting an inflection point as its innovative pipeline finally transitions from R&D costs to commercial revenue, narrowing the gap with industry leaders.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for ELAN. Not financial advice.
Price · last 12 months
Gossip
The narrative has shifted from 'struggling spinoff' to 'innovation turnaround.' Market chatter is dominated by the FDA approval of Zenrelia and Credelio Quattro, which are expected to aggressively challenge Zoetis's dominance in the dermatology and parasiticide markets.
- ·Blockbuster potential for new product launches in 2024/2025
- ·Activist investor pressure (Ancora) driving operational efficiency
- ·Successful divestiture of the aqua business to sharpen focus
Financial
While debt levels remain a historical concern, margins are expanding as the product mix shifts toward higher-margin innovation. The company is successfully deleveraging using proceeds from recent divestments.
- ·Forward P/E around 18x, significantly cheaper than peer average
- ·Deleveraging target of 3-4x Net Debt/Adj. EBITDA by late 2025
- ·Expected double-digit EPS growth driven by pipeline commercialization
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Strong conviction — insiders and patient capital are backing this.
- ·Insiders bought a net $1.5M on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·High execution risk on global product launches
- ·Significant debt load compared to smaller biotech peers
- ·Intense competition from Zoetis in the pet dermatology space
Peer temperature
How direct competitors stack up against ELAN right now.
- NEUTRALZTSZoetis Inc.
COLDER — trading at a premium 30x+ P/E with slowing growth in core brands compared to Elanco's incoming catalysts.
See full analysis → - HOTIDXXIDEXX Laboratories
HOTTER — maintains superior margins and a recurring revenue 'moat' through diagnostic recurring consumables that ELAN lacks.
See full analysis → - COLDPAHCPhibro Animal Health
COLDER — restricted by heavy exposure to livestock and lower-margin nutritional products versus ELAN's high-margin pet health pivot.
See full analysis →
- ELAN-6.6%
- ZTS+1.9%
- IDXX-8.4%
- PAHC+6.2%
Analyst price target
Consensus average of 9 analysts · median 32.00
Source: StockAnalysis.com · updated 2026-08-24
AI-generated analysis for informational purposes only. Not financial advice.